remacemide has been researched along with stiripentol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patsalos, PN; Sander, JW | 1 |
| Bialer, M | 1 |
2 review(s) available for remacemide and stiripentol
| Article | Year |
|---|---|
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsy; Felbamate; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Isoxazoles; Lamotrigine; Levetiracetam; Nipecotic Acids; Oxcarbazepine; Phenobarbital; Phenylcarbamates; Piracetam; Propylene Glycols; Risk Factors; Tiagabine; Topiramate; Triazines; Vigabatrin; Zonisamide | 1994 |
Comparative pharmacokinetics of the newer antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolanes; Felbamate; Flunarizine; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Lamotrigine; Nipecotic Acids; Oxcarbazepine; Phenylcarbamates; Propylene Glycols; Tiagabine; Topiramate; Triazines; Vigabatrin | 1993 |